SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 31, 2018--
Vaxart, Inc. (NASDAQ:VXRT), a clinical stage biotechnology company
developing oral recombinant vaccines that are administered by tablet
rather than by injection, today announced that Roberto Mateo, Ph.D.,
lead scientist of Vaxart, will present data on the Phase 1 norovirus
vaccine trial in a poster presentation at the American Society of
Microbiology 2018, taking place from June 7-11, 2018 in Atlanta, Georgia.
Details of the presentation are as follows:
Presentation Title:
|
|
|
|
Cross Reactivity Following Oral Norovirus Vaccination in Humans
and Ferrets
|
Date & Time:
|
|
|
|
Sunday, June 10, 2018 from 12:45 PM – 2:45 PM EST
|
Authors:
|
|
|
|
Roberto Mateo, et al.
|
Session:
|
|
|
|
Vaccines and Immunization Science; Viruses and Pertusis
|
|
|
|
|
|
“We continue to be encouraged by the cross reactivity data from our
norovirus vaccine program and look forward to sharing it with thought
leaders in infectious disease and microbiology this month at ASM
Microbiome,” said Sean Tucker, Ph.D., founder and chief scientific
officer of Vaxart.
All recent publications are available on the Vaxart website under
Newsroom at www.vaxart.com.
About Vaxart
Vaxart is a clinical-stage biotechnology company focused on developing
oral recombinant protein vaccines based on its proprietary oral vaccine
platform. Vaxart’s vaccines are designed to generate broad and durable
immune responses that protect against a wide range of infectious
diseases and may be useful for the treatment of chronic viral infections
and cancer. Vaxart’s vaccines are administered using a convenient room
temperature-stable tablet, rather than by injection. Vaxart believes
that tablet vaccines are easier to distribute and administer than
injectable vaccines, and have the potential to significantly increase
vaccination rates. Vaxart’s development programs include oral tablet
vaccines that are designed to protect against norovirus, seasonal
influenza and respiratory syncytial virus (RSV), as well as a
therapeutic vaccine for human papillomavirus (HPV). Vaxart is also
developing several small-molecule antiviral drug candidates, including
teslexivir (BTA074), an antiviral treatment for condyloma caused by HPV
types 6 and 11. For more information, please visit www.vaxart.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release regarding
our strategy, prospects, plans and objectives, beliefs and expectations
of management are forward-looking statements. These forward-looking
statements may be accompanied by such words as “believe,” “could,”
“potential” and other words and terms of similar meaning. Examples of
such statements include, but are not limited to, statements relating to
the Vaxart’s ability to develop and commercialize its product
candidates. Vaxart may not actually achieve the plans, carry out the
intentions or meet the expectations or projections disclosed in our
forward-looking statements and you should not place undue reliance on
these forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various important factors
could cause actual results or events to differ materially from the
forward-looking statements that Vaxart makes, that Vaxart’s product
candidates may not be approved by the FDA or non-U.S. regulatory
authorities; that, even if approved by the FDA or non-U.S. regulatory
authorities, Vaxart’s product candidates may not achieve broad market
acceptance; and the risks described from time to time in the reports
Vaxart files with the Securities and Exchange Commission, or SEC,
including its Form 10-Q for the three months ended March 31, 2018.
Copies of reports filed with the SEC are posted on Vaxart’s website and
are available from Vaxart without charge. Vaxart does not assume any
obligation to update any forward-looking statements, except as required
by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180531006477/en/
Source: Vaxart, Inc.
Stern Investor Relations
Carl Mauch, 212-362-1200
vaxart@sternir.com